ASH 2018 A first stem cell transplant after CAR TCell therapy reduces relapses in ALL

ASH 2018: A first stem cell transplant after CAR T-Cell therapy reduces relapses in ALL

In a new study presented at ASH 2018 in San Diego, patients with ALL who received a first stem cell transplant after CD19 CAR T-cell therapy were less likely to experience a relapse of their cancer when compared to similar patients who didn’t undergo...

More From BioPortfolio on "ASH 2018: A first stem cell transplant after CAR T-Cell therapy reduces relapses in ALL"